Home/Filings/8-K/0001104659-26-001774
8-K//Current report

OMEGA HEALTHCARE INVESTORS INC 8-K

Accession 0001104659-26-001774

$OHICIK 0000888491operating

Filed

Jan 6, 7:00 PM ET

Accepted

Jan 7, 4:16 PM ET

Size

193.5 KB

Accession

0001104659-26-001774

Research Summary

AI-generated summary of this filing

Updated

Omega Healthcare Investors Amends Executive Contracts; Raises Bonus/Severance

What Happened Omega Healthcare Investors, Inc. (OHI) filed an 8-K (Item 5.02) reporting that, effective January 1, 2026, it amended the employment agreements of its named executive officers to extend each term through December 31, 2028 and to revise annual salaries per the Compensation Committee’s review. The amendments include material changes for President Matthew Gourmand and Chief Legal Officer & General Counsel Gail Makode.

Key Details

  • Amendments effective January 1, 2026; employment terms extended to December 31, 2028.
  • For Matthew Gourmand: annual bonus opportunity increased from 125%→200% (high), 75%→125% (target), 50%→75% (threshold) of base salary. Severance multiple increased from 2x to 3x the sum of annual base salary plus three‑year average bonus, payable over three years. Post‑termination non‑compete/non‑solicit period extended from 2 years to 3 years.
  • For Gail Makode: severance multiple increased from 1.5x to 2x the sum of annual base salary plus three‑year average bonus, payable over two years. Post‑termination non‑compete/non‑solicit period extended from 18 months to 2 years.
  • Annual salary revisions were made per the Compensation Committee’s review; specific salary amounts were not disclosed. Full amendment text will be filed as an exhibit to OHI’s Q1 2026 Form 10‑Q.

Why It Matters These amendments increase potential cash and benefit obligations to key executives (higher bonus caps and larger severance multipliers) and lengthen post‑employment restrictive covenants, signaling a focus on retention and protection of company relationships. For investors, this may affect future compensation expense and governance considerations; the company has not disclosed specific salary or cash impact in the 8‑K, so look for the Q1 2026 10‑Q for the full amendment text and any financial disclosures.